
Description:
The gradual advancement and innovation of new diabetic care technologies have formed a concrete platform for the further growth of Continuous Glucose Monitoring (CGM) Systems market. With the emergence of advanced technologies such as mobile health, smart sensors, wearable technologies, and 3D-printing into the field of diabetic care, there has been a rise in the overall demand of the newly developed CGM devices. Presently, the focus of the government initiatives is mainly towards developing non-invasive solutions, controlling the level of increase in diabetic population, and integrating advanced technologies to fulfill the unmet needs of the diabetic population.

Governmental regulations and standards are playing a major role in sustaining the growth and development of the CGM Systems market. The main aim of these regulations is to make the device more adaptable and attentive towards different types of diabetic conditions as well as to provide modern mobile technologies to the diabetic population. The patients benefit indirectly through these regulations as it helps them to save time and cuts-down the overall cost of monitoring devices as the patients receive the required treatment for the disease.

The market growth is propelled due to factors such as: increasing demand for non-invasive treatments, technological innovation and advancements, increasing diabetic population, and Medicare & reimbursement policies, among others.

This study includes an overview and analysis of the CGM Systems market, by components end user groups, applications, and geography, allowing the research to develop a comprehensive outlook of the market. The market report presents a detailed and analytical study of the entire market and provides a comprehensive insight into various forms of developments, trends and key participants. The type of diabetes are categorized into three major categories, viz. type 1, type 2, and gestational in the report. All of the above mentioned report coverage parameters are discussed across different regions such as North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW).

While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, associations, and regulatory bodies, and their involvement in the CGM Systems market.

The answers to the following key questions can be found in the report:

- What are the major drivers, challenges and opportunities of the CGM Systems market and their use cases?
- How is the blood glucose monitoring device market evolving?
- What are the driving and restraining factors in the blood glucose monitoring device market?
- What are the market shares of the leading segments of the CGM Systems market in 2015?
- How will each component of the CGM Systems grow over the forecast period and how much revenue will these account for in 2022?
- How will the market shares of the leading national markets change by 2022 and which country will lead the market in 2022?
- How will the industry evolve during the period between 2016 and 2022?
- What are the key developmental strategies implemented in different applications across all regions?
- How will the key market players leverage on key developments such as mergers & acquisitions, partnerships, and product launches among others?
- Which geographical region will lead the global CGM Systems market by the end of the forecast period?
- Who are the key players in the CGM Systems market?
- What are different end user groups in this market and how are they categorized?
- What are the different applications in which CGM devices are being used?
- What are the different used case scenarios considered under different applications?
- What are the market trends and key developments in different geographical regions?

The research study tries to answer various aspects of the CGM Systems market with the help of central factors driving the market, threats that can possibly slow down the overall market growth, and the current
growth opportunities that are going to shape the future trajectory of the market expansion. The study takes into account Porter’s Five Force model and opportunity matrix for an in-depth study of the CGM Systems market and an assessment of the factors governing the same.

Contents:

Executive Summary

1 The Research Scope and Methodology
1.1 Scope of the Report
1.2 Global Continuous Glucose Monitoring (CGM) Systems Market Research Methodology

2 Market Dynamics
2.1 Market Drivers
2.1.1 High Prevalence of Diabetic Population
2.1.2 Patients Involvement in Healthcare
2.1.3 Proliferation of Smartphones and Wearable Devices into Healthcare
2.1.4 Prevalence of Overweight and Obesity in Selected Countries
2.1.5 Medicare and Reimbursements
2.2 Market Challenges
2.2.1 Stringent Regulations and Standards
2.2.2 Requirement of Enormous Time and Training by Patients
2.2.3 High Cost of Device
2.3 Market Opportunities
2.3.1 Evolution of Artificial Pancreas
2.3.2 Innovation of Non-Invasive Glucose Monitoring Devices

3 Competitive Insights
3.1 Key Market Developments & Strategies
3.1.1 Product Launch and Development
3.1.2 Collaborations, Joint Ventures & Partnerships
3.1.3 Business Expansion and Contracts
3.1.4 Patent, Approvals and Certifications
3.1.5 Mergers and Acquisitions
3.1.6 Other Strategies
3.2 Industry Attractiveness

4 Industry Analysis
4.1 Patent Analysis
4.2 Consortium, Association and Regulatory Bodies
4.3 Value Chain Analysis

5 The Global CGM Systems Market Analysis & Forecast
5.1 Assumptions for Analysis and Forecast of the Global CGM Systems Market
5.2 Market Overview
5.2.1 Type of Diabetes
5.2.1.1 Type 1 Diabetes
5.2.1.2 Type 2 Diabetes
5.2.1.3 Gestational Diabetes
5.2.2 Emerging Technologies & Trends in CGM Systems
5.3 Global Continuous Glucose Monitoring (CGM) System Market by End User Group
5.3.1 Children and Teens
5.3.2 Youth
5.3.3 Middle Elderly and Aged
5.4 Global Continuous Glucose Monitoring (CGM) System Market by Components
5.4.1 Insulin Pumps
5.4.2 Sensors
5.4.3 Transmitters & Receivers
5.5 Global Continuous Glucose Monitoring (CGM) Systems Market by Applications
5.5.1 Households/Home Setting
5.5.2 Hospitals
5.5.3 Clinics & Diagnosis Centres
5.6 Global Continuous Glucose Monitoring (CGM) Systems Market by Geography
5.6.1 North America
5.6.2 Europe
5.6.3 APAC
5.6.4 Rest of the World (ROW)

6 Company Profiles
6.1 Abbott
6.1.1 Company Overview
6.1.2 Financials
6.1.2.1 Financial Summary
6.1.3 SWOT Analysis
6.2 AstraZeneca
6.2.1 Company Overview
6.2.2 Financials
6.2.2.1 Financial Summary
6.2.3 SWOT Analysis
6.3 Bayer Healthcare AG
6.3.1 Company Overview
6.3.2 Financials
6.3.2.1 Financial Summary
6.3.3 SWOT Analysis
6.4 Becton Dickinson & Co.
6.4.1 Company Overview
6.4.2 Financials
6.4.2.1 Financial Summary
6.4.3 SWOT Analysis
6.5 Dexcom, Inc.
6.5.1 Company Overview
6.5.2 Financials
6.5.2.1 Financial Summary
6.5.3 SWOT Analysis
6.6 Eli Lilly and Company
6.6.1 Company Overview
6.6.2 Financials
6.6.2.1 Financial Summary
6.6.3 SWOT Analysis
6.7 Johnson & Johnson
6.7.1 Company Overview
6.7.2 Financials
6.7.2.1 Financial Summary
6.7.3 SWOT Analysis
6.8 Medtronic Incorporation
6.8.1 Company Overview
6.8.2 Financials
6.8.2.1 Financial Summary
6.8.3 SWOT Analysis
6.9 Novo Nordisk
6.9.1 Company Overview
6.9.2 Financials
6.9.2.1 Financial Summary
6.9.3 SWOT Analysis
6.10 Roche
6.10.1 Company Overview
6.10.2 Financials
6.10.2.1 Financial Summary
6.10.3 SWOT Analysis
6.11 Sanofi Pharma
6.11.1 Company Overview
6.11.2 Financials
6.11.2.1 Financial Summary
6.11.3 SWOT Analysis
6.12 Tandem Diabetes Care, Inc.
6.12.1 Company Overview
6.12.2 Financials
6.12.2.1 Financial Summary
6.12.3 SWOT Analysis
6.13 Ypsomed
6.13.1 Company Overview
6.13.2 Financials
6.13.2.1 Financial Summary
6.13.3 SWOT Analysis
6.14 Snapshot of Other Prominent Players
6.14.1 Julphar Diabetes
6.14.2 GlySens
6.14.3 Glucovation
6.14.4 Nova Biomedical
6.14.5 Ascensia Diabetes Care
6.14.6 Echo Therapeutics
6.14.7 Insulet Corporation
6.14.8 Omron Healthcare
6.14.9 A. Menarini Diagnostics
6.14.10 Arkray Inc.

List of Tables
Table 3.1 Product Launch and Development
Table 3.2 Collaborations, Joint Ventures & Partnerships
Table 3.3 Business Expansion and Contracts
Table 3.4 Patent and Approvals
Table 3.5 Mergers and Acquisitions
Table 3.6 Others
Table 4.1 Example of Some Recent Patents
Table 4.2 Example of Some Regulatory Bodies, Associations, & Consortia
Table 5.1 Hyperglycemia in Pregnancy in Women aged 20-49 Years by Region, 201
Table 5.2 Number of Diabetic Patients in Major Countries
Table 5.3 Global CGM Systems Market Value by End User Group, 2015-202
Table 5.4 Global CGM Systems Market Value by Components, 2015-202
Table 5.5 Global CGM Systems Market Value by Applications, 2015-2022
Table 5.6 Global CGM Systems Market Value by Geography, 2015-2022
Table 5.7 Diabetes in North America, 2014 (20-79 Years)
Table 5.8 North America: CGM Systems Market Value by End User Group ($Million), 2015-2022
Table 5.9 Diabetes in Europe, 2014 (20-79 Years)
Table 5.10 Europe: CGM Systems Market Value by End User Group, 2015-2022
Table 5.11 Diabetes in APAC, 2014 (20-79 Years)
Table 5.12 APAC: CGM Systems Market Value by End User Group ($Million), 2015-2022
Table 5.13 Diabetes in RoW, 2014 (20-79 Years)
Table 5.14 RoW: CGM Systems Market Value by End User Group ($Million), 2015-2022

List of Figures
Figure 1 Relation between the Total Population and Diabetic Population Worldwide
Figure 2 Global CGM Systems Market Trends
Figure 3 Global CGM Systems Market Value ($Million), 2015-202
Figure 4 Global CGM Systems Market Value by Components ($Million), 2015-202
Figure 5 Global CGM Systems Market Value by End User Group ($Million), 2015-202
Figure 6 Global CGM Systems Market Value by Applications ($Million), 2015-202
Figure 7 Global CGM Systems Market Value by Geography ($Million), 2015-202
Figure 8 Global CGM Systems Market Scenario, 2015 and 202
Figure 1.1 Global CGM Systems Market Scope
Figure 1.2 Secondary Data Sources
Figure 1.3 Top Down Approach
Figure 1.4 Global CGM Systems Market Influencing Factors
Figure 1.5 Assumptions and Limitations
Figure 2.1 Global CGM Systems Market: Market Dynamics
Figure 2.2 Global CGM Systems Market Drivers
Figure 2.3 Obesity Prevalence Rate: Top Five Countries
Figure 2.4 Global CGM Systems Market Challenges
Figure 6.2 Abbott: Revenue across Different Geographies, 2013-2015
Figure 6.3 Abbott: Net Revenue by Business Segment, 2013-2015
Figure 6.4 Abbott: SWOT Analysis
Figure 6.5 AstraZeneca: Overall Financials, 2013-2015
Figure 6.6 AstraZeneca: Revenue across Different Geographies, 2013-2015
Figure 6.7 AstraZeneca: SWOT Analysis
Figure 6.8 Bayer Healthcare AG: Overall Financials, 2013-2015
Figure 6.9 Bayer: Revenue across Different Geographies, 2013-2015
Figure 6.10 Bayer: Net Revenue by Business Segment, 2013-2015
Figure 6.11 Bayer: SWOT Analysis
Figure 6.12 BD & Co.: Overall Financials, 2013-2015
Figure 6.13 BD & Co.: Revenue across Different Geographies, 2013-2015
Figure 6.14 BD & Co.: Net Revenue by Business Segment, 2013-2015
Figure 6.15 BD & Co.: SWOT Analysis
Figure 6.16 Dexcom: Overall Financials, 2013-2015
Figure 6.17 Dexcom: SWOT Analysis
Figure 6.18 Eli Lilly: Overall Financials, 2013-2015
Figure 6.19 Eli Lilly: Revenue across different Geographies, 2013-2015
Figure 6.20 Eli Lilly: Net Revenue by Business Segment, 2013-2015
Figure 6.21 Eli Lilly: SWOT Analysis
Figure 6.22 Johnson & Johnson: Overall Financials, 2013-2015
Figure 6.23 Johnson & Johnson: Revenue across different Geographies, 2013-2015
Figure 6.24 Johnson & Johnson: Net Revenue by Business Segment, 2013-2015
Figure 6.25 Johnson & Johnson: Net Revenue by Business Sub-segment, 2013-2015
Figure 6.26 Johnson & Johnson: SWOT Analysis
Figure 6.27 Medtronic: Overall Financials, 2013-2015
Figure 6.28 Medtronic: Revenue across Different Geographies, 2013-2015
Figure 6.29 Medtronic: Net Revenue by Business Segment, 2013-2014
Figure 6.30 Medtronic: Net Revenue by Business Segment, 2015
Figure 6.31 Medtronic: SWOT Analysis
Figure 6.32 Novo Nordisk: Overall Financials, 2013-2015
Figure 6.33 Novo Nordisk: Revenue across Different Geographies, 2013-2015
Figure 6.34 Novo Nordisk: Net Revenue by Business Segment, 2013-2015
Figure 6.35 Novo Nordisk: SWOT Analysis
Figure 6.36 Roche: Overall Financials, 2013-2015
Figure 6.37 Ingersoll Rand: Revenue across Different Geographies, 2013-2015
Figure 6.38 Roche: Net Revenue by Business Segment, 2013-2015
Figure 6.39 Roche: SWOT Analysis
Figure 6.40 Sanofi: Overall Financials, 2013-2015
Figure 6.41 Sanofi: Revenue across Different Geographies, 2013-2015
Figure 6.42 Sanofi: Net Revenue by Business Segment, 2013-2015
Figure 6.43 Sanofi: SWOT Analysis
Figure 6.44 Tandem Diabetic Care, Inc.: Overall Financials, 2013-2015
Figure 6.45 Tandem: SWOT Analysis
Figure 6.46 Ypsomed: Overall Financials, 2013-2015
Figure 6.47 Ypsomed: Revenue across Different Geographies, 2013-2015
Figure 6.48 Ypsomed: Net Revenue by Business Segment, 2013-2015
Figure 6.49 Ypsomed: SWOT Analysis

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3987750/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Web Address: http://www.researchandmarkets.com/reports/3987750/
Office Code: SC2G457O

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 3399</td>
</tr>
<tr>
<td>Hard Copy</td>
<td></td>
<td>USD 3654 + USD 56 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4674</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 5524</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>USD 3999 - Until 15th Apr 2017</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>USD 4299 - Until 15th Apr 2017</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>USD 5499 - Until 15th Apr 2017</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>USD 6499 - Until 15th Apr 2017</strong></td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.
* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Title:

Fax Number:

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ___________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World